Tech Company Financing Transactions
Verseau Therapeutics Funding Round
On 10/22/2019, Verseau Therapeutics landed $50 million in investment from 20/20 HealthCare Partners, 3SBio and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
10/22/2019
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds from the financing will support advancement of Verseau's macrophage checkpoint modulator (MCM) programs to the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
47 Wiggins Ave.
Bedford, MA 01730
USA
Bedford, MA 01730
USA
Phone
Undisclosed
Website
Email Address
Overview
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. With our proprietary all-human translational system we identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christine Bunt
Chief Financial Officer
Robert Crane
Chief Scientific Officer
Tatiana Novobrantseva
Co-Founder
Igor Feldman
Browse more venture capital transactions:
Prev: 10/22/2019: Upstream Security venture capital transaction
Next: 10/22/2019: Instabase venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs